| dc.description.abstract | ABSTRACT
Malaria remains one of the most deadly infectious disease in sub-Saharan Africa accounting for
high rates of mortality and morbidity especially in children less than 5 years. Plasmodium
falciparum (Pj) parasite causes the most virulent form of malaria partially due to development of
high levels of resistance against most anti-malaria drugs used. In malaria holoendemic areas of
western Kenya, P falciparum drug resistance has been noted since 1980s. Various genetic
mutations have been identified and associated with P f resistance to drugs, such as chloroquine
(CQ), sulphadoxine-pyrimethamine (SP) and recently, Artemisinin-based combination therapy
(ACT). Even though previous studies in Kanyawegi in western Kenya have addressed the
presence of the genes associated with antimalarial resistance at one-time point, the prevalence
and temporal stability of the genes associated with ACT resistance in this malaria holoendemic
population have not been reported. As such the temporal stability in the prevalence of pfcrt
(K76T), pfmdr 1 (N86Y), pfdhfr (C59R) and pfdhps (K540E), and the association within and
between the mutations that confer resistance against anti-malarials and those considered
predictive of ACT treatment failure was investigated at the height of SP resistance just before
administration of the ACT drug (July 2004), four weeks after administration of ACT (August
2004), and 5 years (July 2009) after SP withdrawal as front line treatment for uncomplicated
malaria infections. A total of 95 paired retrospective blood samples from children under 5 years,
confirmed positive for P fwere used. Using Polymerase Chain Reaction (PCR) and Nested PCR,
pfcrt K76T, pfmdr 1 N86Y, pfdhfr (C59R) and pfdhps (K540E) genes were amplified and
presence of mutations determined by gel electrophoresis after Restriction Fragment Length
Polymorphism. Using chi-square analysis to determine the prevalence and Pearson's Correlation
Co-efficient to determine the association between the genotypes and drug failures, the prevalence
of Pfdhps wild type 540K increased from 14.7% (n =14/95) in July 2004 to 53.7% (n=51/95) in
August 2004 (p=0.0004) and subsequently to 94.1% (16117) in July 2009 (p=0.015). For Pfdhfr
wild type C59, the prevalence in July 2004 was 0.0% (n =0/95) and 1.1% (n=1/95) (p=0.144) in
August 2004 and 0.0% (n = 0/17) in July 2009. The prevalence of Pfmdrl wild type 86N was
insignificant (p=0.223) from 0.0% (n=0/95) in July 2004 to 2.1% (n =2/95) in August 2004 and
reduced to 0.0% (n = 0117) in July 2009 (p = 0.759). Prevalence of Pfcrt wild type 76T remained
constant in July and August 2004 at 2.1% (n=2/95) and rose to 5.9% (n=1117) in 2009 (p=0.138).
The prevalence of the K76T mutation was persistent in isolates from this highly holoendemic
area indicating that selection for the mutant codon is in progress while results showed the
absence of the pfmdr 1 N86Y isolates from both the baseline and the follow up isolates
suggesting that the parasites harbouring this mutation are not widespread in this area and there
was continued rise in the prevalence of the mutations associated with SP resistance while there
was no association between the pfcrt K76T and pfmdr 1 N86Y pre- and post-adoption of ACT.
Findings presented here suggest that resistant markers against CQ and SP have not faded and as
suchnot recommended antimalarials in this Pfholoendemic region. This study will complement
existing data on anti-malarial drug resistance monitoring and enhance future prediction of
resistance levels that would be critical in informing anti-malarial drug policy aimed at reducing
malaria-related morbidity and mortality. | en_US |
